Abstract
Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 578-583 |
| Number of pages | 6 |
| Journal | Nishinihon Journal of Urology |
| Volume | 69 |
| Issue number | 10 |
| Publication status | Published - 2007 |
Fingerprint
Keywords
- Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
- National Institutes of Health chronic prostatitis symptom index (NIH-CPSI)
- Nerve growth factor (NGF)
ASJC Scopus subject areas
- Urology
Cite this
Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome. / Watanabe, Toyohiko; Uehara, Shinya; Araki, Daishi; Inoue, Miyabi; Monden, Koichi; Saika, Takashi; Nasu, Yasutomo; Kumon, Hiromi; Yokoyama, Teruhiko.
In: Nishinihon Journal of Urology, Vol. 69, No. 10, 2007, p. 578-583.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nerve growth factor in prostatic fluid as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome
AU - Watanabe, Toyohiko
AU - Uehara, Shinya
AU - Araki, Daishi
AU - Inoue, Miyabi
AU - Monden, Koichi
AU - Saika, Takashi
AU - Nasu, Yasutomo
AU - Kumon, Hiromi
AU - Yokoyama, Teruhiko
PY - 2007
Y1 - 2007
N2 - Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.
AB - Nerve growth factor (NGF) plays a key role as the peripheral mediator of several types of painful inflammatory conditions. In search of new biomarkers with which to more clearly define chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we investigated whether or not NGF in expressed prostatic secretions (EPS) is correlated with symptom severity in CP/CPPS. All CP/CPPS patients underwent a complete history and physical examination, including the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). EPS samples from 16 patients and 3 asymptomatic controls were collected and frozen. The levels of NGF in EPS were measured by enzyme-linked immunosorbent assay. Patients were asked to complete the questionnaires of NIH-CPSI at baseline and at 8 weeks after treatment. Responders for treatment were defined as a 25% decrease in total NIH-CPSI score from the baseline values. Mean NGF in EPS of CP/CPPS patients and asymptomatic controls were 7,555 ± 3,990 pg/ml and 4,374 ± 825 pg/ml, respectively. The levels of NGF in CP/CPPS patients were correlated directly with pain severity (P = 0.042, r = 0.521), but were not correlated with urinary symptoms or the quality of life. There were no significant differences between pre-treatment and post-treatment levels of NGF in EPS. However, in responders, NGF levels were significantly decreased after successful treatment (P = 0.0165). NGF might contribute to the pathophysiology of CP/CPPS. The NGF level in EPS can change according to pain severity. Therefore, these results suggest that nerve growth factor could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.
KW - Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
KW - National Institutes of Health chronic prostatitis symptom index (NIH-CPSI)
KW - Nerve growth factor (NGF)
UR - http://www.scopus.com/inward/record.url?scp=35948967597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35948967597&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:35948967597
VL - 69
SP - 578
EP - 583
JO - Nishinihon Journal of Urology
JF - Nishinihon Journal of Urology
SN - 0029-0726
IS - 10
ER -